As of 14 July 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC). The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments continue reading : HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
[FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Digital Health Technologies (DHT)
Published on 08 July 2026 This is to update all our stakeholders that the Health Technology Assessment (HTA) Council has completed the Philippine HTA Methods Guide for Assessing Digital Health Technologies [DRAFT]. This is part of our ongoing efforts to develop specific HTA Methods Guides across different health technologies. This new methods guide shall complement continue reading : [FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Digital Health Technologies (DHT)
[FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Preventive and Promotive Health (PPH) Technologies
Published on 08 July 2026 This is to update all our stakeholders that the Health Technology Assessment (HTA) Council has completed the Philippine HTA Methods Guide for Assessing Preventive and Promotive Health Technologies [DRAFT]. This is part of our ongoing efforts to develop specific HTA Methods Guides across different health technologies. This new methods guide continue reading : [FOR PUBLIC CONSULTATION] Draft Philippine HTA Methods Guide for Assessing Preventive and Promotive Health (PPH) Technologies
HTA Council Preliminary Recommendation on ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for Adult Hospitalized Patients ≥18 years with Hospital-Acquired Pneumonia (HAP) or Ventilator-Acquired Pneumonia (VAP)
As of 08 July 2026, the HTA Council has completed the evidence appraisal on the assessment of ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for the treatment of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) in adult hospitalized patients ≥18 years. As a continue reading : HTA Council Preliminary Recommendation on ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for Adult Hospitalized Patients ≥18 years with Hospital-Acquired Pneumonia (HAP) or Ventilator-Acquired Pneumonia (VAP)
HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic continue reading : HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults